ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

被引：6
|
作者：
Nichetti, Federico [1 ]
Lo Russo, Giuseppe [1 ]
Prelaj, Arsela [1 ]
Provenzano, Leonardo [1 ]
de Braud, Filippo [1 ,2 ]
Cabiddu, Mary [3 ]
Garassino, Marina Chiara [1 ]
Petrelli, Fausto [3 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy
来源：
THROMBOSIS RESEARCH | 2020年 / 194卷
关键词：
Non-Small-Cell Lung Cancer; Thromboembolic events; Thrombosis; ALK; ROS-1; Tyrosine kinase inhibitors; VENOUS THROMBOEMBOLISM;
D O I：
10.1016/j.thromres.2020.06.041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：176 / 177
页数：2
相关论文
共 50 条
  • [31] Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 71 - 80
  • [32] Immunoexpression of BAP1, ROS1, and ALK in Spitzoid Melanocytic Tumors
    Cardili, Leonardo
    Viana, Cristiano Ribeiro
    Germano, Andressa
    Fernandes, Mariana
    Barcellos, Denise
    Landman, Gilles
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2018, 26 (06) : 514 - 520
  • [33] Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations
    Wang, H. -Y.
    Wu, S. -G.
    Lin, Y. -T.
    Chen, C. -Y.
    Shih, J. -Y.
    ESMO OPEN, 2022, 7 (06)
  • [34] Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
    Dai, Yinghuan
    Liu, Ping
    He, Wenlong
    Yang, Lizhen
    Ni, Yang
    Ma, Xuejiao
    Du, Furong
    Song, Chao
    Liu, Yang
    Sun, Yi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Validating ROS1 Rearrangements As a Therapeutic Target in Non-Small-Cell Lung Cancer
    Solomon, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 972 - 974
  • [36] Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer
    Dyrbekk, Anne Pernille Harlem
    Warsame, Abdirashid Ali
    Suhrke, Pal
    Ludahl, Marianne Odnakk
    Moe, Joakim Oliu
    Eide, Inger Johanne Zwicky
    Lund-Iversen, Marius
    Brustugun, Odd Terje
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
  • [37] Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
    Collier, T. Lee
    Maresca, Kevin P.
    Normandin, Marc D.
    Richardson, Paul
    McCarthy, Timothy J.
    Liang, Steven H.
    Waterhouse, Rikki N.
    Vasdev, Neil
    MOLECULAR IMAGING, 2017, 16 : 1 - 3
  • [38] Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization The Importance of Probe Design
    Uguen, Arnaud
    Marcorelles, Pascale
    De Braekeleer, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : E83 - E85
  • [39] Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
    Drilon, Alexander
    Ou, Sai-Hong Ignatius
    Cho, Byoung Chul
    Kim, Dong-Wan
    Lees, Jeeyun
    Lin, Jessica J.
    Zhu, Viola W.
    Ahns, Myung-Ju
    Camidge, D. Ross
    Nguyen, Judy
    Zhai, Dayong
    Deng, Wei
    Huang, Zhongdong
    Rogers, Evan
    Liu, Juliet
    Whitten, Jeff
    Lim, John K.
    Stopatschinskaja, Shanna
    Hyman, David M.
    Doebele, Robert C.
    Cui, J. Jean
    Shaw, Alice T.
    CANCER DISCOVERY, 2018, 8 (10) : 1227 - 1236
  • [40] Progress of non-small-cell lung cancer with ROS1 rearrangement
    Yang, Xin
    Tang, Zhe
    Li, Jing
    Jiang, Jizong
    Liu, Yue
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
12345